<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The spectrum of adipose tissue diseases ranges from <z:hpo ids='HP_0001513'>obesity</z:hpo> to <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo>, and is accompanied by <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> syndrome, which promotes the occurrence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> and cardiovascular complications </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0009125'>Lipodystrophy</z:hpo> refers to a group of <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare diseases</z:e> characterized by the generalized or partial absence of adipose tissue, and occurs with or without <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> of adipose tissue in other sites </plain></SENT>
<SENT sid="2" pm="."><plain>They are classified as being familial or acquired, and generalized or partial </plain></SENT>
<SENT sid="3" pm="."><plain>The genetically determined partial forms usually occur as <z:e sem="disease" ids="C1720860" disease_type="Disease or Syndrome" abbrv="FPLD2|FPL2">Dunnigan syndrome</z:e>, which is a type of laminopathy that can also manifest as muscle, cardiac, neuropathic or progeroid involvement </plain></SENT>
<SENT sid="4" pm="."><plain>Gene mutations encoding for PPAR-gamma, Akt2, CIDEC, perilipin and the ZMPSTE 24 enzyme are much more rare </plain></SENT>
<SENT sid="5" pm="."><plain>The genetically determined generalized forms are also very rare and are linked to mutations of seipin AGPAT2, FBN1, which is accompanied by <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, or of BANF1, which is characterized by a <z:e sem="disease" ids="C0009207" disease_type="Disease or Syndrome" abbrv="">progeroid syndrome</z:e> without <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and with early bone complications </plain></SENT>
<SENT sid="6" pm="."><plain>Glycosylation disorders are sometimes involved </plain></SENT>
<SENT sid="7" pm="."><plain>Some genetically determined forms have recently been found to be due to autoinflammatory syndromes linked to a proteasome anomaly (PSMB8) </plain></SENT>
<SENT sid="8" pm="."><plain>They result in a <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> syndrome that occurs secondarily with <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:e sem="disease" ids="C0037274" disease_type="Disease or Syndrome" abbrv="">dermatosis</z:e> and <z:mp ids='MP_0011164'>panniculitis</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Then there are forms that are considered to be acquired </plain></SENT>
<SENT sid="10" pm="."><plain>They may be iatrogenic (<z:chebi fb="0" ids="37670">protease inhibitors</z:chebi> in HIV patients, glucocorticosteroids, insulin, <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, etc.), related to an <z:e sem="disease" ids="C0021053" disease_type="Disease or Syndrome" abbrv="">immune system disease</z:e> (sequelae of <z:e sem="disease" ids="C0011633" disease_type="Disease or Syndrome" abbrv="">dermatopolymyositis</z:e>, autoimmune polyendocrine syndromes, particularly associated with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:e sem="disease" ids="C0220989" disease_type="Disease or Syndrome" abbrv="">Barraquer</z:e>-<z:e sem="disease" ids="C0220989" disease_type="Disease or Syndrome" abbrv="">Simons</z:e> and <z:e sem="disease" ids="C0221032" disease_type="Disease or Syndrome" abbrv="">Lawrence syndromes</z:e>), which are promoted by anomalies of the complement system </plain></SENT>
<SENT sid="11" pm="."><plain>Finally, <z:e sem="disease" ids="C0023801" disease_type="Disease or Syndrome" abbrv="">lipomatosis</z:e> is currently classified as a painful form (<z:e sem="disease" ids="C0001529" disease_type="Disease or Syndrome" abbrv="">adiposis dolorosa</z:e> or <z:e sem="disease" ids="C0001529" disease_type="Disease or Syndrome" abbrv="">Dercum's disease</z:e>) or benign symmetric multiple form, also known as <z:e sem="disease" ids="C0024445" disease_type="Neoplastic Process" abbrv="MSL">Launois-Bensaude syndrome</z:e> or <z:e sem="disease" ids="C0023801" disease_type="Disease or Syndrome" abbrv="">Madelung's disease</z:e>, which are sometimes related to <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> DNA mutations, but are usually promoted by alcohol </plain></SENT>
<SENT sid="12" pm="."><plain>In addition to the medical management of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and the sometimes surgical treatment of <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo>, recombinant leptin provides hope for genetically determined <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> syndromes, whereas modifications in antiretroviral treatment and tesamorelin, a GHRH analog, is effective in the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> of HIV patients </plain></SENT>
<SENT sid="13" pm="."><plain>Other therapeutic options will undoubtedly be developed, dependent on pathophysiological advances, which today tend to classify genetically determined <z:hpo ids='HP_0009125'>lipodystrophy</z:hpo> as being related to laminopathy or to <z:chebi fb="23" ids="18059">lipid</z:chebi> droplet disorders </plain></SENT>
</text></document>